glp 1 drugs and cancer GLP-1 may have a beneficial effect across many types of GLP-1 Receptor Agonists in Solid
Description
Meyer-Gerspach, A

Targeting Glucose-Dependent Insulinotropic Polypeptide Receptor for Neurodegenerative Disorders

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
:max_bytes(150000):strip_icc()/VWHealth-Could-GLP-1Drugs-Reduce-Obesity-Related-Cancers-in-the-Future-3-7d602ab39c0448ddb00cd91b06be2a84.jpg)
Med 89 , 457464 (2022)
PMID: 25202980

You still enjoy eating, but it doesnt drive behavior in the same way. That mechanism has sparked interest far beyond obesity research
